Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
PHASE2CompletedINTERVENTIONAL
Enrollment
114
Participants
Timeline
Start Date
November 30, 1997
Study Completion Date
September 30, 2000
Conditions
MelanomaNeoplasm Metastasis
Interventions
BIOLOGICAL
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001685 - Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase | Biotech Hunter | Biotech Hunter